Chroma Medicine is developing epigenetic editing technologies that modify chromatin structure to precisely regulate gene expression without altering the DNA sequence. This approach aims to create durable genomic therapies for diseases that currently lack effective treatments.
Funding
$135M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases lack effective treatments due to the limitations of traditional gene therapies that permanently alter the DNA sequence. These methods can lead to unintended consequences and are not suitable for conditions requiring precise and reversible gene regulation.
Solution
Chroma Medicine is developing epigenetic editing technologies that modify chromatin structure to precisely regulate gene expression without altering the underlying DNA sequence. This approach allows for durable yet reversible control over gene activity, offering a new class of genomic medicines. By harnessing the power of epigenetics, Chroma aims to create therapies that can precisely control gene expression, leading to more effective and safer treatments for a wide range of diseases. This innovative approach promises unparalleled control of gene expression, addressing the limitations of existing gene therapies.
Target Audience
Chroma Medicine's primary focus is on patients suffering from diseases that currently lack effective treatments and can benefit from precise and durable gene regulation.
Features
- Epigenetic editing technology that modifies chromatin structure.
- Precise regulation of gene expression without altering the DNA sequence.
- Durable and reversible control over gene activity.